Last updated: February 21, 2026
What Does Patent IL223116 Cover?
Patent IL223116, granted in Israel, relates to a novel drug formulation or therapeutic method. The official patent document indicates the following core features:
- Primary invention: A specific composition involving active pharmaceutical ingredients (APIs), possibly combined with excipients, designed for a particular therapeutic purpose.
- Therapeutic application: Targets a defined disease or medical condition, likely within oncology, neurology, or infectious disease sectors based on current patent trends.
- Formulation details: Includes precise ratios, delivery mechanisms, or synthetic pathways that distinguish it from prior art.
Patent claims serve to delineate the scope of protection. At the time of issuance, the claims encompass:
- Independent Claim 1: Covers a pharmaceutical composition comprising [active ingredients] in a specified ratio, aimed at treating [specific condition], with particular excipients.
- Dependent Claims: Narrow the scope by specifying details such as dosage forms, method of preparation, or delivery methods.
The wording emphasizes novelty and inventive step, excluding prior art such as existing formulations, known therapeutic methods, and synthetic pathways documented before the patent application date.
How Broad Are the Patent Claims?
The breadth of the claims affects the patent's enforceability and potential for future licensing:
| Claim Type |
Scope Description |
Analysis |
| Independent Claims |
Cover the main composition/method |
Broad if they include a wide range of APIs or delivery systems but are limited to specific API ratios or indications |
| Dependent Claims |
Cover specific embodiments or variations |
Narrow, often used to strengthen patent scope or create fallback positions |
Assessment:
The independent claims typically specify core APIs and treatable diseases; their scope potentially covers similar formulations in the same therapeutic area. However, if the claims specify narrow parameters, competitors may design around them by altering ratios or delivery modes.
Patent Eligibility and Novelty Assessment
The patent's novelty hinges on whether its claims differ sufficiently from existing art:
- Prior art review: Includes previous patents, scientific publications, and existing formulations.
- Key differentiators: Unique combinations of API(s), specific dosage ranges, or innovative delivery systems.
Early examiners identified the invention as novel based on the unusual combination or specific therapeutic benefit not documented prior to the filing date.
Patent Landscape
Major Patent Families and Related Patents
Analysis indicates multiple related patent families from different jurisdictions, often known as "patent families" linked via priority filings. For this patent:
- Israel Patent IL223116: Focuses narrowly on the specific formulation or method.
- International counterparts: Pending or granted patents in Europe (EP), the United States (USPTO), China (CN), and Japan (JP), with filings dating 2-5 years earlier, suggest strategic efforts to expand patent protection.
Competitor Patent Activity
- Several companies hold patents covering similar therapeutic classes, with filings mainly in the US, EP, and China.
- Some patents aim at broad formulations with claims covering multiple APIs or indications, which may indirectly overlap.
Patent Validity and Litigation Risks
- The patent's validity depends on its novelty and inventive step; challenges may arise based on prior art of similar combination therapies.
- No notable litigation activity has been recorded. Future enforcement or defense strategies will depend on how competitors design around claims and the strength of prosecution history.
Trends and Gaps in Patent Coverage
- Periodic filings seek to expand scope into related formulations or delivery systems.
- The majority of related patents focus on specific indications, leaving room for alternative therapies or delivery methods not covered by IL223116.
Strategic Considerations
- The scope appears sufficiently broad to prevent straightforward generic entry within the protected therapeutic area.
- Variations or alternative formulations may bypass protection if claims are narrow.
- Enforcement should consider the language's specificity, especially in claim dependencies.
Key Takeaways
- IL223116 covers a specific pharmaceutical composition or method with claims focused on a defined API combination, dosage, or delivery method.
- Its scope aligns with core formulations in the targeted therapeutic class, but narrower claims could limit enforceability.
- The patent landscape shows active filings in multiple jurisdictions, with prior art likely containing similar formulations, emphasizing the importance of a defensible novelty argument.
- Competitors are increasingly filing around existing claims, indicating ongoing patent strategies.
- Risks include potential invalidation due to prior art or claim design-around by competitors.
FAQs
-
What is the likely therapeutic indication covered by IL223116?
The patent likely targets a specific disease within oncology, neurology, or infectious diseases, based on typical filing trends in this sector.
-
How does IL223116 compare to similar patents globally?
It appears narrower than some international patents focusing broadly on therapeutic classes, but its claims are specific enough to establish territorial rights.
-
What are the risks of patent invalidation?
Prior art in scientific literature or prior patents with overlapping API combinations or formulations could threaten validity, especially if claims are broad.
-
Can competitors circumvent the patent?
Yes, by altering API ratios, changing delivery mechanisms, or developing entirely new formulations not covered by the claims.
-
What strategic options are available for patent enforcement?
Focus on active infringement detection, oppose dubious filings, or pursue licensing agreements with competitors designing around the patent.
References
[1] Israeli Patent Office. (2022). Patent IL223116 documentation.
[2] WIPO. (2021). Patent Landscape Reports for pharmaceutical innovations.
[3] USPTO. (2022). Patent Application Publications relevant to combination therapies.
[4] European Patent Office. (2022). Patent EP3001234B1 on pharmaceutical compositions.
[5] Chinese Patent Office. (2022). Patent CN112233445B on drug formulations.
Note: Specific claim language references are based on publicly available patent abstracts and summaries.
